Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia*

View at Publisher

Ask AI

Bookmark

Share

Key Points

To evaluate the effectiveness of endolysin Cpl-1 as a treatment for severe pneumococcal pneumonia in mice.
In vivo study using female C57/Bl6 mice infected with pneumococci.
Mice treated with Cpl-1 or amoxicillin post-infection either 24 or 48 hours after.
Survival rates and pulmonary bacterial counts measured post-treatment.
100% survival in Cpl-1-treated mice and 86% in amoxicillin-treated when therapy started 24 hours post-infection.
42% survival with Cpl-1 and 71% with amoxicillin when treatment initiated 48 hours post-infection.
Cpl-1 significantly reduced pulmonary bacterial counts and improved overall clinical parameters compared to untreated mice.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Controlled lab study demonstrates Cpl-1 improves survival in mice with pneumococcal pneumonia, suggesting a new treatment option.

No takes yet. Share an insight, caveat, or question.

Witzenrath et al. (2009) studied this question.

View at Publisher

Ask AI

Bookmark

Share